SCHEMBL293767

SCHEMBL293767

CC(=O)NCCC=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL293574 0.85
SCHEMBL14590766 0.83 HIF1A (0.65)
SCHEMBL8107 0.83 KDM4E (0.71)
SCHEMBL404097 0.82
SCHEMBL204637 0.81 KDM4E (0.70)
SCHEMBL9636118 0.81 KDM4E (0.70)
SCHEMBL15743759 0.81 KDM4E (0.70)
SCHEMBL19606333 0.81 KDM4E (0.70)
SCHEMBL8810970 0.81 KDM4E (0.70)
SCHEMBL29951519 0.81 KDM4E (0.70)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 200 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190285632-A1 METABALOMICS AND VIRAL DIAGNOSTICS SUITE EXCISION BIOTHERAPEUTICS, INC. (US) 2019-09-19 US claimed
EP-3510148-A1 HIV CLINICAL PLAN Excision Biotherapeutics, Inc. (US) 2019-07-17 EP claimed
US-20190194652-A1 HIV CLINICAL PLAN EXCISION BIOTHERAPEUTICS, INC. (US) 2019-06-27 US claimed
CN-109689866-A HIV clinical program 切除生物治疗公司 2019-04-26 CN claimed
EP-3465213-A1 METABALOMICS AND VIRAL DIAGNOSTICS SUITE Excision Biotherapeutics, Inc. (US) 2019-04-10 EP claimed
CN-109154610-A Metabolomics and Viral Diagnostic Kits 切除生物治疗公司 2019-01-04 CN claimed
US-20180340202-A1 Method for Rapid High Volume Production of Synthetic Vaccines POSTREL RICHARD (US) 2018-11-29 US claimed
WO-2018049372-A1 HIV CLINICAL PLAN EXCISION BIOTHERAPEUTICS INC (US) 2018-03-15 WO claimed
WO-2017205460-A1 METABALOMICS AND VIRAL DIAGNOSTICS SUITE EXCISION BIOTHERAPEUTICS, INC. (US) 2017-11-30 WO claimed
EP-2185713-A2 PROCESS FOR PREPARING CHIRAL COMPOUNDS Pfizer Products Inc. (US) 2010-05-19 EP claimed
WO-2009019561-A2 PROCESS FOR PREPARING CHIRAL COMPOUNDS PFIZER PRODUCTS INC. (US) 2009-02-12 WO claimed
EP-1893767-A1 PROCESS FOR PRODUCING ATORVASTATIN, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AND INTERMEDIATES THEREOF Pfizer, Inc. (US) 2008-03-05 EP claimed
WO-2006134482-A1 PROCESS FOR PRODUCING ATORVASTATIN, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AND INTERMEDIATES THEREOF PFIZER INC. (US) 2006-12-21 WO claimed
US-4226870-A ANTIBIOTICS, BACTERICIDES MERCK & CO., INC. (US) 1980-10-07 US claimed
EP-0001265-A1 O-, N- and carboxyl derivatives of thienamycin sulfoxide and sulfone, their preparation and pharmaceuticals containing said compounds MERCK & CO. INC. (US) 1979-04-04 EP claimed
EP-4181781-B1 BREATH-BASED THERAPEUTIC DRUG MONITORING METHOD UNIV KINDERSPITAL BEIDER BASEL (CH) 2026-05-20 EP disclosed
EP-4729603-A2 METABOLOMIC CHARACTERIZATION OF MICROORGANISMS Lewis, Ian Andrew (CA) 2026-04-22 EP disclosed
EP-0382185-A2 Carbostyril derivatives OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1990-08-16 EP disclosed
US-4062947-A Di-N-alkylaminoglycosides, methods for their manufacture and novel intermediates useful therein, method for their use as antibacterial agents and pharmaceutical compositions useful therefor SCHERING CORPORATION (US) 1977-12-13 US disclosed
US-4002742-A 1-N-alkyl-4,6-di-(aminoglycosyl)-1,3-diaminocyclitols, methods for their manufacture, methods for their use as antibacterial agents, and compositions useful therefor SCHERING CORPORATION (US) 1977-01-11 US disclosed